The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)
pathway is activated in the majority of human cancers. This pathway is known to play a key …

Metastasis is a distinct stage of cancer progression that requires the development of
angiogenic blood vessels serving as conduits for tumor cell dissemination. An accumulated …

Yes‐associated protein (YAP) has been identified as a key driver for epidermal growth factor
receptor‐tyrosine kinase inhibitor (EGFR‐TKI) resistance. Inhibition of YAP expression could …

New vessel formation (angiogenesis) is an essential physiological process for embryologic
development, normal growth, and tissue repair. Angiogenesis is tightly regulated at the …

Background Lenvatinib is an oral inhibitor of multiple receptor tyrosine kinases (RTKs)
targeting vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor …

Adaptation of cancer cells to their microenvironment is an important driving force in the
clonal selection that leads to invasive and metastatic disease. O 2 concentrations are …

Resistance towards chemotherapy, either primary or acquired, represents a major obstacle
in clinical oncology. Three basic categories underlie most cases of chemotherapy failure …

Angiogenesis—the process of new blood-vessel growth—has an essential role in
development, reproduction and repair. However, pathological angiogenesis occurs not only …

Recent clinical trials using rapalogues in tuberous sclerosis complex show regression in
volume of typically vascularised tumours including angiomyolipomas and subependymal …

Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …